As part of its expansion strategy to the South American Market, IMeBIO, a global provider of mobile/modular biocontainment laboratory solutions had the opportunity to announce its strategic partnership with BioSafe Brasil, a leader local biosafety company during HOSPITALAR 2023 at SAO PAULO Brazil, South America’s leading healthcare tradeshow for professionals in the hospital and public health sector.

This partnership marks a significant milestone for both organizations and holds great potential for advancing biosafety practices and standards in the region. By combining IMeBIO’s expertise in mobile biocontainment facility design and construction with BioSafe’s deep understanding of the local biosafety landscape, this collaboration aims to offer comprehensive solutions that meet the evolving needs of the South American biopharmaceutical and health industry.



For more than 10 years IMeBIO has been designing and manufacturing mobile/modular solutions in maritime containers, we have installed more than 40 laboratories BSL2/BSL3 and GMP worldwide adapting our products to local conditions. As part of our after-sales service scope, we offer maintenance, tele maintenance, and qualification for laboratories.



Headquartered in Sao Paulo and present throughout the national territory, Biosafe Brazil, active since 2005 they are specialized and pioneers in consultancy, design, construction, maintenance, bio-decontamination, and certification of NB3-type environments.


Meeting Growing Demands in South America:

The expansion of IMeBIO to South America comes at a crucial time when the biopharmaceutical industry in the region is experiencing substantial growth, driven by a combination of factors such as increasing healthcare investments, rising demand for innovative therapies, favourable regulatory reforms, and a focus on local production capabilities. With an increasing number of research and development activities, there is a growing demand for advanced biocontainment facilities that adhere to international biosafety standards. IMeBIO’s decision to partner with BioSafe demonstrates its commitment to supporting the South American market and addressing the specific biosafety requirements of local biopharma companies.


By combining their resources, knowledge, and networks and leveraging their complementary strengths, IMeBIO and Biosafe are poised to drive innovation, enhance safety standards, streamline manufacturing processes, and facilitate market access, benefiting patients worldwide, and shaping the future of healthcare.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *